-2%
- Osteoporosis results from an imbalance in bone breakdown (resorption) and formation. Salost DR reduces bone resorption by inhibiting osteoclasts, leading to increased bone density and decreased fracture risk.
- Risedronate binds to hydroxyapatite crystals in bone and acts as an antiresorptive agent by reducing osteoclast activity while allowing normal bone adhesion.

